Can CAR T Cells Be Reprogrammed to Outsmart Cancer?

Conventional CAR T-cell therapies are engineered to recognize a specific tumor antigen, but that fixed targeting can become a limitation when cancer cells lose the antigen or express different targets. In an interview with Pharmacy Times, Christine Brown, PhD, and John Williams, PhD, of City of Hope discuss a preclinical meditope-enabled platform designed to give engineered T cells additional functions without rebuilding the cellular product.

Brown explains that the technology creates a modular system in which adapter molecules can redirect CAR T cells before or after infusion. Williams emphasizes that this flexibility could allow researchers to combine targeting strategies, rather than relying on a single antigen throughout treatment.

The investigators demonstrated expanded tumor recognition by redirecting HER2-targeted CAR T cells toward CD19 and PD-L1. Because antibodies linked to the meditope peptide can serve as adapters, the platform offers a potential approach to addressing tumor heterogeneity and antigen escape. However, whether this strategy can prevent relapse or improve outcomes in patients remains unproven. Williams identifies adapter pharmacokinetics and antigen density among the factors requiring further investigation.

The discussion also explores using the platform to deliver IL-15 to engineered T cells. Brown describes findings showing that a meditope-linked IL-15 adapter supported CAR T-cell expansion in laboratory experiments and mouse models, with a dose-dependent response. This proof of concept suggests a possible way to adjust expansion after infusion when cellular persistence is insufficient.

Williams notes that other cytokines or stimulatory molecules could eventually be explored through the same platform. Brown adds that future work will investigate combining support for T-cell persistence with broader antigen recognition.

Together, these findings establish an early foundation for adaptable CAR T-cell therapy. The researchers emphasize that the results remain preclinical, and further studies are needed to determine how these functions translate into safe and effective treatment for patients with cancer.